UK seeks own Breakthrough Therapy program

Share this article:

The UK is looking to create a Breakthrough Therapy regulatory pathway. Bloomberg reports that Under Secretary of State Frederick Curzon told an audience at the Empower Access to Medicines meeting that the government was “at an advanced stage” of establishing an expedited approval process similar to the FDA's.

The US set up the program in 2012, and has received 92 requests. Genentech's Gazyva, J&J/Pharmacyclics Imbruvica and Gilead's Sovaldi are among the breakthrough therapy designated drugs that have been approved.

Bloomberg notes that while the European Medicines Agency still governs what gets approved for the region, Britain's Medicines and Healthcare Products Regulatory Agency has say over how clinical trials are conducted and monitored in the UK.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Sanofi wants greater MS role

The plan is to bring in-house products to the market as well as through acquisitions.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.